Recovering scientist turned early stage VC A biotech optimist fighting gravity

Where Does All That Biotech Venture Capital Go?
February 9, 2015

Venture capital investing in biotech has long been hard to disaggregate: how much goes to “early stage” vs “late stage”, how much goes to CNS vs oncology, discovery vs Phase 3, etc… Today BIO’s David Thomas and Chad Wessel have


Data Snapshot: VC-Backed BioPharma M&A 2014
February 3, 2015

Similar to this time last year, when IPOs were capturing everyone’s attention, M&A in biotech has been delivering real value.  This morning HBM Partners released their outstanding report on BioPharma M&A in 2014 (here), and the conclusions are in line

Leave a comment

Infusing Biotech With Young Blood
January 30, 2015

This blog was written by Michael Gladstone, Principal at Atlas Venture, as part of the “From the Trenches” feature of LifeSciVC. Youth is often well represented among entrepreneurs – except in biotech. William Osler, founder of Johns Hopkins University and the


Venture-Backed Biotech Today: Reflections On Exits, Funding, and Startup Formation
January 22, 2015

Biotech is definitely red-hot, and has been for the past eight quarters. Immuno-oncology, cancer metabolism, gene therapy, orphan diseases, NASH, autoimmune – there’s a broad range of disease settings that are capturing the excitement and imagination of investors today. With some


Persistent Vitality At #JPM15
January 20, 2015

This blog was written by Kevin Pojasek, Founder and acting CEO of Quartet Medicine, as part of the “From the Trenches” feature of LifeSciVC. A favorite quote from the Jazz Age king that nicely captures life as a biotech entrepreneur.  Breaking

Leave a comment

Things I Expect To Hear At #JPM15
January 9, 2015

Are you ready for the circus?  Next week’s JPM Healthcare Conference is getting ready to kickoff, and much of the healthcare industry is feverishly preparing their materials for the mayhem. Given the biopharma industry pipeline’s exciting clinical progress, a record-breaking

Leave a comment

Immuno-Oncology: Scratching the Surface
January 8, 2015

Another day, another announcement about great data from immuno-oncology.  It’s clearly one of the hottest fields in biopharma today, and has been for a few years.  The opening paragraph of a recent Leerink report by Seamus Fernandez and team on

1 Comment

Rekindling The Flame
December 18, 2014

This blog was written by Mike Gilman, Atlas’ EIR and CEO of Padlock Therapeutics, as part of the “From the Trenches” feature of LifeSciVC. I thought I was done with immunology. I’m not formally trained as an immunologist, but I fell for it hard


Company Culture: Continuation On A LifeSciVC Theme
December 11, 2014

This blog was written by Jeff Hatfield, CEO of Vitae Pharmaceuticals, as part of the “From the Trenches” feature of LifeSciVC. Over the past two weeks in LifeSciVC, I read with great interest and appreciation the blogs of two friends of


Deck The Halls With… Compensation Committees
December 10, 2014

It’s that time of year again: Santa is preparing his list of naughty and nice biotech management teams, and taking his recommendations to the Compensation Committee. As I’ve been sitting through several of these meetings already, I thought it would

1 Comment

Riding The Biotech Roller Coaster Like A Pro: Some Observations
December 1, 2014

This blog was written by Ankit Mahadevia, Atlas EIR and c0-founder of Spero and Rodin Therapeutics, as part of the “From the Trenches” feature of LifeSciVC. As startup folks we are great at keeping our heads down and looking ahead; this

Leave a comment

It’s the People, Stupid:  Building and Maintaining a High Performance Corporate Culture
November 25, 2014

Building a performance based corporate culture is a key aspect of the biotech innovation business.  It can be easy to overlook this facet of company building as one focuses on determining the robustness of the new technology, refining your business

Leave a comment